Actelion Announces U.S. Commercial Availability of OPSUMIT® (macitentan) as of November 4

05-11-2013 Business Wire HealthComments (0)


Actelion (SIX: ATLN) today announced the commercial availability of OPSUMIT® (macitentan) 10mg, an oral, dual endothelin receptor antagonist (ERA) approved for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression. PAH is a chronic, life-threatening disorder that can severely compromise the function of the lungs and heart. The U.S. Food and Drug Administration (FDA) approved OPSUMIT on October 18, 2013. OPSUMIT® is indicated fo

Read more on Business Wire Health

More on this story...

Actelion says PAH drug Opsumit now available in USA

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top